We always think of our customers with an open mind
Press Release
NTL Healthcare Participates in the Korean Society of Obstetrics and Gynecology (Direct Election) Spring Academic Conference
Author
엔티엘헬스케어
Date
2023-05-31 11:46
Views
180
NTL Healthcare Participates in the Korean Society of Obstetrics and Gynecology (Direct Election) Spring Academic Conference
On the 8th, NTL Healthcare announced that it had successfully promoted its products at the ‘12th Korean Society of Obstetrics and Gynecology (direct election) Spring Academic Conference.’
On the 5th, NTL Healthcare participated in the ‘12th Korean Society of Obstetrics and Gynecology (direct election) Spring Academic Conference’ held at the Swiss Grand Hotel in Seodaemun-gu, Seoul, and showed various products, including ▲CerviCARE®, which is platform for integrated screening of cervical and women's diseases, ▲Dr.Cervicam C20, which is cervical magnification imaging and reading device, ▲JILL' SOF, which is automatic drug injection in the vagina, ▲Dilapan-S, which is cervical dilatation, ▲POCT (HUBI-QUAN PRO), which is on-site pregnancy diagnosis, and ▲SCD Sleeve, which is sequential compression device.
In particular, CerviCARE® is an integrated screening platform for cervical and women's diseases that has incorporates medical expertise accumulated over 27 years. At this event, NTL Healthcare showed its artificial intelligence (AI)-based cervical cancer image reading and screening system. CerviCARE® AI is a software that assists medical professionals in their decision-making. Based on cervical images big data, it can distinguish between normal (negative) and abnormal (positive) cervical images, as well as classify normal images into normal and atypical images. The CerviCARE® AI is currently in the process of cooperative clinical trials with eight university hospitals, including Guro Hospital at Korea University.
Tae-hee Kim, CEO of NTL Healthcare, stated that "CerviCARE® AI will be used to assist medical professionals in making diagnostic decisions during cervical cancer screening. We will continue to develop the CerviCARE®, integrated screening platform that considers the convenience of medical professionals, and provide high-quality medical services and build a healthy future for women."
Meanwhile, NTL is a group consisting of NTL Healthcare, which develops cervical cancer screening device and software, and NTL Medical Institute, which provides screening services to clinics and hospitals. NTL, a company that introduced cervical magnification imaging and reading system in Korea in 1996, provides various screening services such as cancer screening for women, including cervical cancer screening, and continues to develop and supply new products that can improve women's health.
On the 8th, NTL Healthcare announced that it had successfully promoted its products at the ‘12th Korean Society of Obstetrics and Gynecology (direct election) Spring Academic Conference.’
On the 5th, NTL Healthcare participated in the ‘12th Korean Society of Obstetrics and Gynecology (direct election) Spring Academic Conference’ held at the Swiss Grand Hotel in Seodaemun-gu, Seoul, and showed various products, including ▲CerviCARE®, which is platform for integrated screening of cervical and women's diseases, ▲Dr.Cervicam C20, which is cervical magnification imaging and reading device, ▲JILL' SOF, which is automatic drug injection in the vagina, ▲Dilapan-S, which is cervical dilatation, ▲POCT (HUBI-QUAN PRO), which is on-site pregnancy diagnosis, and ▲SCD Sleeve, which is sequential compression device.
In particular, CerviCARE® is an integrated screening platform for cervical and women's diseases that has incorporates medical expertise accumulated over 27 years. At this event, NTL Healthcare showed its artificial intelligence (AI)-based cervical cancer image reading and screening system. CerviCARE® AI is a software that assists medical professionals in their decision-making. Based on cervical images big data, it can distinguish between normal (negative) and abnormal (positive) cervical images, as well as classify normal images into normal and atypical images. The CerviCARE® AI is currently in the process of cooperative clinical trials with eight university hospitals, including Guro Hospital at Korea University.
Tae-hee Kim, CEO of NTL Healthcare, stated that "CerviCARE® AI will be used to assist medical professionals in making diagnostic decisions during cervical cancer screening. We will continue to develop the CerviCARE®, integrated screening platform that considers the convenience of medical professionals, and provide high-quality medical services and build a healthy future for women."
Meanwhile, NTL is a group consisting of NTL Healthcare, which develops cervical cancer screening device and software, and NTL Medical Institute, which provides screening services to clinics and hospitals. NTL, a company that introduced cervical magnification imaging and reading system in Korea in 1996, provides various screening services such as cancer screening for women, including cervical cancer screening, and continues to develop and supply new products that can improve women's health.
